Meeting
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
Authors
Marytere Herrera
Gastrointestinal Oncology Unit, Mexico City, Mexico;
Marytere Herrera , Andrea Maliachi Diaz , Consuelo Diaz , Veronica Salais Michaus , Erika Ruiz , Sebastian Garcia , Sayako Miyagui Adame , German Calderillo Ruiz Sr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 683)
DOI
10.1200/JCO.2023.41.4_suppl.683
Abstract #
683
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Impact of new chemotherapy regimens on the treatment landscape and survival of advanced pancreatic cancer (PAC) patients (pts).
First Author: Markus Kieler
Poster
2018 ASCO Quality Care Symposium
Are real-world patient-reported outcomes associated with survival in patients with advanced pancreatic cancer?
First Author: Wei Fang Dai
Poster
2014 ASCO Annual Meeting
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
First Author: Thomas H. Cartwright
Poster
2014 Gastrointestinal Cancers Symposium
Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity.
First Author: Yue Zhang